Jubilant Pharmova develops a novel oral formulation of Remdesivir

Jubilant Pharmova develops a novel oral formulation of Remdesivir

Shares of Jubilant Pharmova has spurted over 7% amid the development of a novel oral formulation of Remdesivir.
Jubilant Pharma, a subsidiary of Jubilant Pharmova announced the successful completion of safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral formulation of Remdesivir against the commercially available injectable formulation of Remdesivir.
Jubilant has sought authorization for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI).

The proposed oral treatment is expected to be for 5 days, a duration similar to the injectable dosage form.
Remdesivir is the first and the only anti-viral drug fully approved by the US FDA for the treatment of patients with COVID-19 requiring hospitalisation, which is in scarcity amid rising cases in the country. Moreover, the government has also capped the price of Remdesivir amid the rising demand for the drug.
The findings from both preclinical and human studies indicate that the drug is able to undergo absorption when administered using the novel oral formulation.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.